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PknB is an essential serine/threonine kinase of Mycobacterium tuberculosis with possible roles in
a number of signalling pathways involved in cell division and metabolism. We screened a library of
>50,000 compounds for inhibitors of the in vitro phosphorylation of GarA (Rv1827) by PknB and iden-
tiﬁed a number of inhibitors. A program of synthetic medicinal chemistry was subsequently conducted
around one class of inhibitors and was successful in generating ATP competitive inhibitors with potency
in the nanomolar range. Compounds in this class showed cross-reactivity with the relatedM. tuberculosis
kinase, PknF, but not with PknG in an in vitro autophosphorylation assay. These synthesised inhibitors
were able to prevent the growth of M. tuberculosis in an Alamar blue assay and in an intracellular model
of infection, but only in the micromolar range. We attempted to determine if cell wall permeability was
an explanation for the discrepancy between the potent in vitro compared with relatively poor in vivo
activity, but found no evidence that the activity of the inhibitors could be improved by weakening
the cell wall. Despite a number of drug discovery efforts attempting to develop inhibitors against PknB,
it is yet to be reported that any such inhibitors prevent mycobacterial growth at submicromolar
concentrations.
 2011 Elsevier Ltd. Open access under CC BY license.1. Introduction
Mycobacterium tuberculosis remains one of the world’s most
devastating pathogens, with more than 13 million people suffering
from an active tuberculosis infection and 1.8 million resulting
deaths in 2008 alone.1 The emergence of multi-drug and exten-
sively drug resistant strains has highlighted the need for new drugsx: þ44 20 8906 4477.
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nse.to treat tuberculosis. Recent studies have focused on ﬁnding new
pathways vulnerable to inhibition by small molecules and previ-
ously unexploited by drug discovery efforts. The inhibition of sig-
nalling pathways both in M. tuberculosis and the host may yield
new classes of drug targets and a large amount of recent work has
focused on developing this further.
Target based drug discovery, in which there is in vitro high
throughput screening of a large number of small molecules against
a validated target, has been used on a number of occasions to search
for new anti-tuberculosis agents. We sought to ﬁnd inhibitors of an
essential M. tuberculosis serine/threonine protein kinase, PknB.
Kinases are attractive as drug targets due to the range of crucial
cellular processes in which they are involved. There has been much
interest in developing ATP competitive kinase inhibitors for the
treatment of cancer, a hallmark of which is often aberrant kinase
activity. A large number of small molecule kinase inhibitors have
been developed as potential anti-cancer drugs and there is a huge
amount of interest in developing kinase inhibitors to treat a range
of conditions.2 Kinase-focused libraries of small molecule inhibitors
have been built-up as a result of these studies and a large amount of
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early success stories from the development of eukaryotic kinase
inhibitors suggested that similar drugs could be developed to treat
bacterial infections. The M. tuberculosis serine/threonine protein
kinases (STPKs) are attractive targets partly because of the inferred
importance of serine/threonine phosphorylation inM. tuberculosis:
M. tuberculosis is unique within the bacterial world in having
a much higher number of STPKs compared to the more common
two-component signalling systems.3e6 Mycobacterium leprae,
during extensive reductive evolution, has lost all but four of these
kinases: PknA, PknB, PknG and PknL.7 PknA and PknB are essential
inM. tuberculosis,8e10 while PknG has been reported to be involved
in survival in the macrophage, either as a result of a role in glu-
tamate metabolism11 or via modulation of host cell trafﬁcking
pathways.12
Previous studies have focused on the potential of PknB and PknG
as drug targets in M. tuberculosis, although the majority have
reported signiﬁcantly less impressive activity against whole cells
than against thepuriﬁedprotein invitro.8,12e14Despite this, there can
benodoubt, fromanumberof lines of evidence, that PknB carries out
function(s) essential to M. tuberculosis, and possesses a number of
properties that suggest it is suitable for development of novel drugs:
a crystal structure has also been determined for PknB15,16 and the
kinase domain exhibits less than 30% similarity with eukaryotic
kinases, which has positive implications for developing a drug
speciﬁc for the bacterial kinases and not those of the host. The pknB
gene (Rv0014c) is part of an operon highly conserved among the
actinomycetes and also encoding pknA, the other essential kinase;
pstP, a phosphoserine/threonine phosphatase; rodA, a cell division
protein; pbpA; a protein involved in peptidoglycan biosynthesis; and
two genes (fhaB and fhaA) coding for forkhead-associated proteins.
Over-expression or depletion of this kinase results in gross changes
in cell morphology, likely a result of the role of PknB in the phos-
phorylation-mediated regulation of a numberof proteins involved in
cell wall biosynthesis.10,17,18 In addition, both PknB and PknG are
known to phosphorylate a protein involved in the regulation of
glutamate metabolism,19e21 suggesting that an inhibitor of one or
both of these kinases could also impact on the ability of
M. tuberculosis to adequately regulate its centralmetabolicprocesses.
Targeting of these bacterial kinases would therefore be a way of
inhibiting evolutionarily-conserved steps in central metabolic
processes.
We screened for smallmolecule inhibitors of PknBand, as a result
of a medicinal chemistry program (manuscript in preparation), our
lead compounds were able to inhibit PknB activity in vitro in the
nanomolar range. However, the potency of our compounds against
whole cells in culture or in amacrophagemodel of infectionwas two
orders of magnitude lower than expected from the in vitro potency.
An often suggested explanation for low anti-tuberculosis activity is
the problem of cell wall permeability. Since the M. tuberculosis cell
wall presents an extremely hydrophobic barrier which can impede
the entry of drugs into the cell, we sought to determine if cell wall
permeabilitymight explain the difﬁculties in improving the potency
of our PknB inhibitors. In addition, we investigated the role of efﬂux
pumps, protein binding in the assay media and inhibitor speciﬁcity
as alternative explanations.
2. Materials and methods
2.1. Compounds
Compounds for the high throughput screening included the
MRCT compound collection comprising 45,000 diverse templates
from commercially available collections, as well as 6400 kinase-
focused templates (Biofocus DPI, Cambridge, UK) selected on thebasis of bio-informatics provided by the crystal structure of PknB
and other serine/threonine kinases. Focused libraries, based around
compounds identiﬁed from the initial screen, were subsequently
generated by synthetic medicinal chemistry.
2.2. Protein expression and puriﬁcation
GarA was expressed in Escherichia coli and puriﬁed as des-
cribed.22 The 279 residue kinase domain of PknB and the 292
residue kinase domain of PknF were expressed as 3C-protease
cleavable GST-fusions in E. coli Rosetta 2 (DE3) pLysS cells. The
proteins were puriﬁed with glutathione Sepharose 4B resin
(GE Healthcare) and the GST-tag cleaved from the protein prior to
elution using 3C protease (GE Healthcare).
2.3. High throughput protein kinase assays
A non-radioactive PknB kinase assay was developed to follow
ATP depletion during the PknB-catalyzed phosphorylation of GarA
(Rv1827). The Promega ‘Kinase Glo’ assay kit was used to measure
levels of phosphorylation via detection of the remaining ATP after
the completion of the kinase reaction. Brieﬂy, luciferase and beetle
luciferin were introduced to the reaction mix and, in the presence
of Mg2þ, ATP and oxygen, the oxygenation of luciferin generates
one photon of light per turnover. PknB activity is inversely
proportional to the intensity of the luminescence signal. Using this
assay format the Km of ATP was determined to be 1.5 mM and ATP
was used at this concentration for screening.
The following reaction mix was prepared: 0.15 mM PknB and
5 mM Rv1827 in reaction buffer (50 mM TriseHCl, 150 mM NaCl,
1 mM DTT and 0.01% Triton X-100). The assay was carried out in
22 ml volumes in 384-well white plates (Matrix, 4316). A Beckman
Biomek Fx liquid handling robot was used to dispense premixed
reaction mix into the wells and the 2 ml of the compound/DMSO
added to a ﬁnal concentration of 10 mM/1% DMSO. The plates were
incubated for 30 min and the reaction initiated with the addition of
1 mM MnCl2/1.5 mM ATP using the Perkin Elmer Flexdrop non-
contact liquid dispenser. The reaction was stopped after 20 min
with the addition of 22 ml Kinase Glo reagent and luminescence
read with a BMG Polarstar reader. Control wells with and without
PknB were included on every plate in columns 1, 2 and 23, 24 and
were used to calculate Z0 values.23 Data from any plates with Z0<0.5
were rejected and were repeated.
2.4. Strains and growth conditions
M. tuberculosis H37Rv, Mycobacterium smegmatis mc2155,
M. smegmatis DfbpA (gift from C. Thompson), and M. tuberculosis
DompA (gift from P. Draper) cultures were grown at 37 C in Dubos
broth supplemented with 0.05% (vol/vol) Tween 80, 0.2% (vol/vol)
glycerol, and 4% (vol/vol) Dubos medium albumin (Becton Dick-
inson). M. smegmatis strains were grown either in 5 ml volumes in
20ml universals or in 50ml volumes in 250mlﬂasks, incubated in an
orbital shaker at 150 rpmat 37 C.M. tuberculosiswas growneither in
100 ml volumes in a Bellco roll-in incubator (2 rpm) or in 10 ml
volumes in static universals. Kanamycin was used at a ﬁnal concen-
tration of 25 mg ml1. M. tuberculosis was grown on 7H11 supple-
mentedwith10%OADCenrichment (Middlebrook) and 0.5% (vol/vol)
glycerol.
2.5. M. tuberculosis minimum inhibitory concentration (MIC)
determination
MICs were determined for M. tuberculosis using a 96-well plate
method with Alamar blue, as described previously.24,25 A modiﬁed
K.E.A. Lougheed et al. / Tuberculosis 91 (2011) 277e286 279version of the assay usedM. smegmatiswith a 3 day incubation. The
cell wall weakening and efﬂux pump inhibition assays were mod-
iﬁcations of the Alamar blue assay, as described in the results.
Z0 values were used as a measure of assay quality, using the
following formula: Z0 ¼ 1e3  SSD/R, where SSD is the sum of the
Standard Deviation of the negative controls and Standard Deviation
of the positive controls, and R is the mean of the maximum signal
control minus the mean of the negative signal control.23
2.6. Intracellular activity of PknB inhibitors in a macrophage
infection by M. tuberculosis
Intracellular inhibition was tested in murine bone marrow-
derived macrophages at a range of concentrations as previously
described.25 Brieﬂy, monocytes were isolated from Balb/c bone
marrow and differentiated with L-cell supernatant for 5e7 days.
Themacrophages were infected withM. tuberculosiswith anMOI of
0.5 bacteria: 1 macrophage for 4 h, and the infection incubated in
the presence of various concentrations of the inhibitors for 5 days.
At this point, the macrophages were lysed with dH20 þ 0.05%
Tween 80 and plated for CFU enumeration. Prior to the infection,
the compounds were tested to rule out any effect of toxicity against
the macrophages. Alamar blue was used to determine macrophage
viability after incubation with the inhibitors (not shown).
2.7. Kinase autophosphorylation assay
In vitro autophosphorylation of PknA, PknB, PknG and PknF
(1 mg) was carried out in 20 ml reaction mixture containing 2.5 ml
buffer P (25mMTriseHCl, pH 7.0,1 mMdithiothreitol, 5mMMgCl2,
1 mM EDTA). The reaction was initiated with the additional of
0.08 mCi [g-32P] ATP and incubated at 37 C for 30 min. The reaction
was terminated with the addition of SDS-PAGE sample buffer and
heating themixture at 100 C for 5min. The reactionmixtures were
analyzed by SDS-PAGE. The gels were soaked in 20% tricholoro-
acetic acid for 10 min at 90 C and dried. Radioactive proteins were
visualized by autoradiography and quantiﬁed by Phosphorimage
analysis using a STORM 840 Optical Scanner System and Image-
Quant (version 5.2, Molecular Dynamics, Sunnyvale, CA). Images
were adjusted for contrast and brightness using Adobe Photoshop.
2.8. Radioactive competition assay
Reactions were set up in a volume of 17 ml kinase buffer (50 mM
TriseHCl pH7.2, 1 mM DTT, 0.01% TX-100) containing 100 nM
puriﬁed PknB and 3 mM puriﬁed Rv1827 and increasing amounts of
each inhibitor diluted in neat DMSO (from 0.03 mM to 100 mM) in
polypropylene U-bottomed 96 well plates. The reactions were
started by the addition of 5 ml of solutions containing MnCl2 and
ATP at Km or 50xKm, to achieve ﬁnal concentrations of 1 mMMnCl2
with 1.5 mM ATP and 0.1 mCi 33P or 75 mM ATP and 1 mCi 33P.
After incubating for 70min at room temperature, reactions were
terminated by the addition of 20 ml 50% orthophosphoric acid.
Reactions were then transferred to a 96 well glass ﬁlter capture
plate (GF/C) and unbound 33P was washed away with 200 ml 1.5%
orthophosphoric acid, using a Tomtec Harvester 9600. After drying
overnight at room temperature, 25 ml scintillant was added to each
well and quantiﬁcation of Rv1827 phosphorylation achieved by
detecting incorporated 33P with the PE Topcount.
2.9. Kinase proﬁling against a panel of mammalian kinases
This was carried out using a 33P-ATP ﬁlter-binding assay26 on
a panel of 70 mammalian kinases at the National Centre for ProteinKinase Proﬁling in the MRC Protein Phosphorylation Unit at the
University of Dundee.2.10. Docking studies with PknB inhibitors
The mitoxantrone bound crystal structure (PDB:2FUM) was
selected for docking studies owing to its greater suitability in terms
of ligand-induced binding site architecture as compared to the ATP
bound structure (PDB:1MRU). Protein preparation, grid generation
and docking (GlideSP) were all carried out using the Schrodinger
molecular modelling suite (Schrodinger LLC: New York. http://
www.schrodinger.com).3. Results
3.1. High throughput screening for PknB inhibitors
PknB has been previously validated as a suitable target for drug
discovery and we sought to identify small molecule inhibitors
targeted against this kinase. A number of potential substrates for
PknB were tested, with GarA (Rv1827) being chosen as the most
strongly phosphorylated protein in our assay. GarA has been
described as an in vivo target for both PknB and PknG19,20 and
interaction with this target is known in some detail.22,27 A non-
radioactive PknB kinase assay was developed to follow ATP
depletion during the PknB-catalyzed phosphorylation of GarA.
Substrate Kms were determined for both ATP (1.5 mM) and Rv1827
(>20 mM). The Km ATP concentrations and an excess of peptide
(5 mM) were selected to achieve a robust assay window >0.5
within the linear phase of the reaction, maximizing sensitivity to
ATP competitive inhibitors.
In total w54,000 compounds were screened against PknB. The
compound collection was sourced by MRCT from commercial
suppliers. Drug-like ﬁlters to assess both physicochemical properties
and known toxicophores were applied to the selection process. The
MRCT library comprisedw44,000 diverse compound collection and
w9000 kinase-focused collection (targeting ATP binding site). In
addition, w1000 natural products (Phytoquest) were screened. The
average Z0 was 0.76 and a conﬁrmed hit rate of 0.14%was observed. In
total, 76 compounds conﬁrmed IC50 in the range 1e200 mM.
Limitations of the Kinase glo assay format did not permit
detailed enzyme kinetics to be performed. However using a radio-
active assay, a number of compounds were assessed for ATP
competitiveness by measuring IC50 at a high (75 mM) and a low
(1.5 mM, Km) ATP concentration. From the ChengePrussoff equa-
tion28 we would predict that for an ATP competitive inhibitor,
a 25-fold shift in IC50 would be seen between ATP at Km (1.5 mM)
and 50XKm (75 mM). Five compounds from the series, including the
original screen hit, with a range of potencies 50e1000 nM in the
primary assay were selected. Fold shifts in the range 15.5e32 were
observed for all compounds, consistent with an ATP competitive
mechanism. It was expected that, due to the higher ATP concen-
tration in the cells compared to the in vitro assay, a shift in MIC
compared to IC50 enzyme activity would be observed. However,
a consistent shift was not observed.
Docking studies (Figure 1) indicate that the compounds should
be ATP competitive. They bind to the hinge region via two H-bonds
between the ligand core and the peptide backbone of Val95 along
with an additional H-bond via the ligand pyrazole NH to the
peptide carbonyl of Glu93. Numerous Van Der Waals contacts
contribute to binding, most notably between the ligand cyclopropyl
group in the hydrophobic pocket towards the Met92 gatekeeper
and also via extensive contact along the glycine rich loop at the
entrance to the binding site.
Figure 2. Compounds inactive against M. tuberculosis had a range of IC50s against the
puriﬁed protein. A similar spread was observed for the compounds able to inhibit
M. tuberculosis. Starred section indicated the area of the graph where compounds
highly active against both the puriﬁed protein and whole cells would appear.
Figure 3. Intracellular activity of PknB inhibitors in a bone marrow derived macro-
phage model. Macrophages were infected with an MOI of 0.5:1 and incubated in the
presence of a dilution series of the inhibitors. After 5 days, the macrophages were lysed
and the intracellular bacteria enumerated by CFU platings. Data is expressed as
percentage survival compared to the untreated control. Inhibitor structures and cor-
responding in vitro activity against puriﬁed protein are shown in Table 1.
Figure 1. Docking of MRCT67127 into PknB active site. Green ribbon represents PknB
(Code: 1MRU) with ATP co-crystallised (shown as green structure). Grey ribbon
represents PknB (Code: 2FUM) with mitoxantrone co-crystallised. The mitoxantrone
structure was removed and docking studies conducted with this PknB conformation:
owing to the ﬂat nature of the docked compounds (making them similar to mitox-
antrone), this was considered a better way to obtain reliable results. MRT67127 is
shown (grey structure) docked into PknB.
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Compounds that showed potent activity against PknB in vitro, no
cytotoxicity and good selectivity against a panel of mammalian
kinases, were tested in an M. tuberculosis Alamar blue MIC assay.
Brieﬂy, 2-fold dilutions of the inhibitors were incubated at 37 C
with approximately 1105 cells per well in 96-well microplates for
7 days. Untreated M. tuberculosis and media only controls were
included on every plate, and the control drugs isoniazid, strepto-
mycin and ethambutol were tested in parallel with each batch of
PknB inhibitors to ensure that the assay was reproducible. The
Alamar blue reagent was added on the ﬁnal day of the incubation,
and the ﬂuorescence measured at the completion of the experi-
ment. A 90% inhibition of ﬂuorescence compared to the untreated
control was chosen as the cutoff for the determination of inhibitory
concentrations. The statistical parameter, Z0-factor, was used as
a measure of assay quality, with a score greater than 0.75 taken as
an indication of good data.
MICs were determined for more than 100 compounds, with
a range of MICs being observed varying between inactive at 250 mM
to inhibitory at 8e16 mM. The compounds were also tested against
M. smegmatis (data not shown) with a generally good agreement
between the two assays. This conﬁrms previously published exper-
iments (e.g.29) which have suggested that testing compounds against
M. smegmatis is a goodmodel for TB drug discovery. Therewas a poor
correlation between IC50 against the puriﬁed recombinant protein
and anti-M. tuberculosis MIC, with the majority of compounds
proving to be inactive against the whole cells. The lack of correlation
between protein and whole cell activity is illustrated in Figure 2.
Despite extensive rounds of chemistry, unfortunately it was not
possible to reduce the M. tuberculosis MICs below the 10 mM level.
3.3. Intracellular activity of PknB inhibitors against M. tuberculosis
in a bone marrow derived macrophage model of infection
A subset of compounds was chosen for further investigation.
The key criteria in this selection included reasonable activity
against M. tuberculosis in vitro, a low MIC to IC50 ratio as a possibleindication of good cell wall permeability, good selectivity against
a panel of human kinases and good physicochemical parameters,
includingmoderate logD and low hydrogen bond donor count, both
of which are requirements for good membrane permeability. The
intracellular activity of these compounds against M. tuberculosis in
a bone marrow derived macrophage model of infection was tested.
The compounds showed a dose dependant inhibition of intra-
cellularM. tuberculosis, although a number of the compounds were
not able to inhibit 99% growth compared to the untreated control
(chosen as the cutoff for determining intracellular inhibition).
Figure 3 shows the inhibition of intracellular growth by the 12 PknB
inhibitors chosen for further investigation. At the lowest concen-
tration tested, 2.5 mM, none of the compounds were able to inhibit
growthbymore than99%of the control. Anumberof the compounds
were active at the higher concentrations of 10 and 20 mM. While
concentrations up to 100 mMwere tested, these are not showndue to
a number of the compounds proving to have toxic effects against the
macrophages, possibly due to inhibition of host kinases.
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between intracellular activity and whole cell inhibition was found.
3.4. Role of cell wall permeability and efﬂux on inhibitor MIC
Poor anti-tuberculosis activity by compounds that are potent in
the in vitro protein assay is often attributed to impermeability of the
M. tuberculosis cell wall. M. tuberculosis has a thick and ‘waxy’ cell
wall, which limits the ability of compounds to penetrate and reach
the cytoplasm.30 Much of the impermeability stems from the
unique mycolic acid layer. While little is known about the speciﬁc
properties of small molecules that enable them to diffuse across the
M. tuberculosis cell wall, it is possible to modify certain functional
groups of the compounds inways that will hopefully improve entry
into the cytoplasm. For example, modiﬁcations were made to our
more active compounds in an attempt to vary the compounds’ LogP
values and increase their hydrophobicity (to be discussed in
a separate medicinal chemistry paper). In one case, it was possible
to improve the MIC/IC50 ratio using this approach. However, the
resulting activity of the compounds againstM. tuberculosiswas still
poor. Before embarking on further chemistry with the hope of
improving cell penetration, we attempted to determine whether
cell wall permeability truly was a major contribution to low MIC
values through the use of several cell wall-weakened models with
the subset of inhibitors shown in Figure 3.
A number of chemicals and antibiotics were tested, including
Triton X-100, glycine, lysozyme, isoniazid and ethambutol. There
have been previous reports of sub-lethal concentrations of antibi-
otics targeted to the cell wall being able to enhance permeability
of certain compounds.31,32 In particular, ethambutol has been
demonstrated to enhance the activity of rifampicin, streptomycin
and isoniazid against drug resistant strains.33 In our experiments,
the cell wall weakening agent was used at 0.5 MIC in conjunction
with the PknB inhibitors to determine whether the inhibitors were
better able to inhibit M. tuberculosis in the presence of a weakened
cell wall. As a control, we demonstrated that the MIC of rifampicin
was reduced by 4-fold in the presence of sub-inhibitory concen-
trations of ethambutol, conﬁrming published data that reported
that accumulation of and sensitivity to rifampicin is enhanced by
ethambutol.34 We tested a number of compounds, including the
subset of 12 active compounds and a number that were previously
inactive against M. tuberculosis. Several compounds were able to
inhibitM. tuberculosis in the presence of ethambutol when they had
been previously inactive. This implied that cell wall permeability
was, indeed, a problem for some structural families. However, the
MICs of the most efﬁcacious compounds were not improved by
ethambutol treatment.
In addition to the ethambutol cell-wall weakened model, we
wanted to use a more deﬁned model. AnM. smegmatis fbpAmutant
has been shown to possess increased sensitivity to a number of
antibiotics due to alterations in its cell wall.35 FbpA is involved in
mycolic acid biosynthesis and the mutant has a loss of cell wall
hydrophobicity compared with the wild type. We tested the
sensitivity of this mutant to the PknB inhibitors and, in agreement
with the ethambutol data, there was no improvement in inhibition
with a weakened cell wall. In comparison, vancomycin MIC was
improved by 16-fold and erythromycin by 8-fold. This effect was
speciﬁc to certain antibiotics as the MICs and streptomycin and
ethambutol were not improved in the assay.
After testing the role of the mycolic acid layer in drug perme-
ability, we sought also to investigate other possible paths of entry
into the cell. Antibiotics can either diffuse across the cell wall,
a possibility investigated in the experiments detailed above, or
alternatively may enter through hydrophilic channels. Porins in the
mycobacterial outer membrane are required for the diffusion ofhydrophilic solutes and are the route of entry for small and hydro-
philic antibiotics such as isoniazid and ethambutol.36 It has been
demonstrated that an mspA porin deletion mutant of M. smegmatis
has a multi-drug resistant phenotype to antibiotics including
ampicillin.37 Although M. tuberculosis does not encode Msp-like
proteins, expression of M. smegmatis MspA in M. tuberculosis enh-
ances antibiotic sensitivity38 and anM. tuberculosis outermembrane
channel-forming protein has been demonstrated to restore antibi-
otic sensitivity to a M. smegmatis mspA mutant.39 One of the best
understoodporins inM. tuberculosis is OmpA, thathas been linked to
the diffusion of pyrazinamide across the cell wall.40 M. tuberculosis
ompAmutants have not been reported to have an antibiotic resistant
phenotype similar to M. smegmatis mspA. Therefore, we tested the
sensitivity of the mutant to a number of antibiotics compared to the
wild type strain. UnlikeM. smegmatismspA,M. tuberculosis ompAdid
not have increased sensitivity to the small, hydrophilic antibiotics
tested. However, it did show a slightly increased resistance to the
large antibiotics vancomycin and erythromycin. This result was also
observed for M. smegmatis mspA, despite both of these antibiotics
being too large to enter the cell via porins. It is likely that alterations
in the cell wall have a knock-on effect on entry of large antibiotics
into the cell. This experiment does not provide any evidence that
small antibiotics enter M. tuberculosis via OmpA channels, but we
cannot rule out that OmpA is involved in the uptake of other anti-
biotics not tested. We also tested the ompA mutant with the PknB
inhibitors and observed that the majority of them were equally
active against the wild type and mutant.
The activity of efﬂux pump inhibitors has been shown to play
a role in the acquired drug resistance ofM. tuberculosis for a number
of antibiotics,41e44 due to the upregulation of efﬂux pumps in drug
resistant strains. It has been suggested that the use of efﬂux pump
inhibitors in conjunction with anti-tuberculosis therapy could be
used to reverse the efﬂux pump-mediated drug resistance in some
infections.45 There is also some evidence that efﬂux plays a role in
the intrinsic drug resistance of mycobacteria.46e48 Therefore, we
tested whether the addition of sub-inhibitory concentrations of the
efﬂux pump inhibitors reserpine and verapamil to our assay would
improve the PknB inhibitor MICS. No change was observed in MIC
at either 20 or 40 mg/ml of either efﬂux pump inhibitor, while the
MIC of the ethidium bromide control was decreased by 4-fold. This
is perhaps not surprising due to the observation that the effect of
efﬂux inhibitors is most dramatic when there is overexpression
or upregulation of efﬂux pumps, rather than against wild type
levels.34,45
3.5. Speciﬁcity of PknB inhibitors
Attempts to select resistant mutants of the 12 most potent PknB
inhibitors were unsuccessful, possibly due to either the high MICs
of the compounds, or non-speciﬁc activity of the inhibitors. We
plated 5  109 M. tuberculosis directly on to media containing 2, 4
and 8MIC inhibitors as well as pre-growing the cells on 0.5 and
1MIC before replating on the above concentrations. Neither
method generated any resistant colonies. This, combined with the
lack of correlation between MIC and activity in the in vitro protein
assay led us to consider whether the inhibitors are truly targeting
PknB. It is possible that some of the anti-tuberculosis activity of the
inhibitors is due to off-target activity, meaning that further PknB-
focused chemistry based around these structural families is un-
likely to lead to an improvement in MIC. Alternatively, despite good
selectivity overmammalian kinases, the inhibitors could be binding
to a number of the other more closely related M. tuberculosis
kinases, and it is possible that the inhibitor is being sequestered
away from PknB by its activity against any of the eight non-
essential kinases in M. tuberculosis.
Table 1
Structures and inhibitor activity against puriﬁed PknB andM. tuberculosis in an Alamar blue and an intracellular assay. IC50 is shown as the mean of three experimental repeats,
Alamar blue and intracellular MIC is representative of three or more repeats.
Inhibitor Structure IC50 PknB mM MIC M. tuberculosis mM* MIC Intracellular mMy
1.MRT67127
N
N
NH
N
H
N
N
N
R
0.053 32 5
2.MRT67153
N
N
NH
N
H
N
O
N
0.056 32 20
3.MRT68667
N
N
Br
NH N
H
N
N
H
O
N
N
0.09 64 20
4.MRT68606
N
N
NH
N
F
F
F
N
N
Br
R
0.519 16 >20
5.MRT68572
N
N
NH
N F
F
F
N
N
R
16.554 16 >20
6.MRT68634
N
N
NH
N
O
N
H
N
N
R
1.499 64 >20
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Table 1 (continued)
Inhibitor Structure IC50 PknB mM MIC M. tuberculosis mM* MIC Intracellular mMy
7.MRT67131
N
N
NH
N
H
N
N
H
N
H
N
0.345 125 >20
8.MRT67150
N
N
NH
N
H
N
ON
0.055 32 5
9.MRT67155
N
N
NH
N
H
N
O
N
N 0.096 64 10
10.MRT67156
N
N
NH
N
H
N
O
N
0.092 16 5
11.MRT67319
N
N
NH
N
N
N
R
6.194 32 10
12.MRT68664
N
N
Br
NH N
H
N
N
H
O
0.065 64 5
* 90% inhibition ﬂuorescence compared to untreated control.
y 99% inhibition compared to untreated control.
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ability of the compounds to inhibit autophosphorylation of some
of the other M. tuberculosis kinases. PknA, the other essential
kinase, was tested but, due to high levels of stable phosphorylation
of this kinase following puriﬁcation, it was not sufﬁciently active in
the assay. Due to the essential nature of PknA, we were not con-
cerned about possible cross-reactivity of the PknB inhibitors with
this kinase. In fact, this could be advantageous for the development
of a TB drug. We also tested the ability of the inhibitors to inhibit
PknF and PknG autophosphorylation. PknG is a soluble kinase
while PknF is membrane-associated like PknB; both are non-
essential.
It was observed that there is a high degree of cross-reactivity
between the PknB inhibitors and PknF, the other membrane-asso-
ciated kinase tested. However, PknG was less strongly inhibited at
the concentrations tested (Figure 4). A possible explanation for this
is the 39.5% sequence identity shared between PknB and PknF
compared to only 27.3% between PknB and PknG.
4. Discussion
PknBhasbeen showntobeanessential protein inM. tuberculosis,8
and is proposed to be involved in a number of vital pathways.
Initially, it was implicated as having a role in cell division due to its
chromosomal locationwithin an operon containing genes known to
be important for these processes. Depletion or overexpression of
PknB results in gross changes in cell morphology, and some of itsFigure 4. In vitro activity of the PknB inhibitors against PknF and PknG. The inhibitors were t
an autophosphorylation assay. There was good agreement between the anti-PknB activity in
was created using the averaged band intensities from three independent autoradiographs.identiﬁed substrates are known to be important for cell wall and
division-related functions.10 The cell wall is known to be a strong
target for anti-tuberculosis drugs, due to its importance for the
survival of the pathogen and its uniqueness. PknB is most strongly
expressed during exponential growth10 and upon infection of
aTHP-1macrophage cell line,49 suggesting that thekinase is involved
in general growth and important during an infection. More recently,
it has been seen that one of PknB’s substrates, GarA, has a role in
intermediary metabolic processes. GarA negatively regulates two
proteins involved in metabolism, 2-hydroxy-3-oxoadipate synthase
and glutamate dehydrogenase and is itself negatively regulated via
phosphorylation by PknB.20e22 Interestingly, GarA is also known to
be phosphorylated in vivo by PknG on a neighbouring threonine to
that phosphorylated by PknB.20
The known functions of PknB detailed above do suggest that
this kinase would be a strong candidate for an anti-tuberculosis
drug. We found a number of inhibitors able to inhibit PknB in vitro
with IC50s in the 20 nM range. The MICs of these inhibitors against
M. tuberculosis were found to be in the 16 mM to inactive range,
despite several rounds of compound optimization. Some shift in
MIC compared to IC50 was expected due to higher intracellular
concentrations of ATP leading to competition. However, a consis-
tent shift was not observed across the series, suggesting additional
mechanisms are involved in the poor activity against whole cells.
It should also be noted that the intracellular concentration of ATP
in M. tuberculosis is in the micromolar range50 (A. Chang, unpub-
lished data), which is signiﬁcantly lower than that the acceptedested at 1 mM (not shown) and 10 mM for their ability to inhibit PknB, PknF and PknG in
this assay and the non-radioactive assay used in the high throughput screen. The graph
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IC50 ratios appear to be a similar result to the published data of
other groups who have also attempted to develop PknB or PknG
inhibitors.8,12e14 This poor activity was evident even in an intra-
cellular assay.
We investigated the role of cell wall permeability, either diffu-
sion through the hydrophobic cell wall or diffusion through hydr-
ophilic channels, and found no evidence that thiswas a limiting step
in the action of the inhibitors. We also investigated the role of efﬂux
and observed that inhibitor activity was not improved in an efﬂux
pump inhibited model.
A possibility is that the more potent inhibitors, which were
chosen for compound optimization, were not targeting PknB in the
cells. A similar problem was described by Payne et al.51 in their
reviewofGlaxoSmithKline’s 7 years of antibacterial high throughput
screen (HTS) research. They attributed the antibacterial activity of
some of their lead compounds to non-speciﬁc membrane interac-
tions that led to cell lysis. We did attempt to determine the in vivo
target of the inhibitors by generating resistant mutants, however
this proved unsuccessful. In a previous study, Fernandez et al. used
M. smegmatis overexpressing PknB to demonstrate that an increase
in PknB levels was able to increase resistance to their PknB inhibi-
tors.8 However, they were only able to see a modest 2-fold increase
in resistance compared to the control strain. Our attempts to
perform a similar experiment in M. tuberculosis proved difﬁcult,
perhaps becauseM. tuberculosis is more sensitive to overexpression
of PknB than M. smegmatis. Even a modest increase in PknB exp-
ressionwas sufﬁcient to slow growth and alter cell morphology, and
the effect of overexpression on inhibitor sensitivity was not signiﬁ-
cant (K.E.A. Lougheed, unpublished data).
It is also possible that PknB may not be bound by the inhibitors
when it is in a physiologically relevant conﬁguration. In other drug
discovery efforts, it has been shown that small molecule inhibitors
are ineffective when their targets are involved in proteineprotein
interactions.52 Such signalling complexes may behave differently in
cells than in solution perhaps because the binding site is masked by
interacting proteins or because of differences in the in vivo protein
conformation compared to the puriﬁed protein against which the
inhibitors were screened.
Although pknB is an essential gene, very low levels of activity
may be sufﬁcient for survival, especially under the conditions we
used to test our compounds. The M. tuberculosis kinases do display
some redundancy, at least in the in vitro screens which have been
used to investigate the substrates of the kinases. It is also possible
that the cross-reactivity of the inhibitors against other kinases or
the binding of alternative proteins results in a sequestering of the
available inhibitor away from PknB. In fact, our results have
demonstrated that themajority of the inhibitors tested are also able
to inhibit PknF in vitro, although PknGwas not as strongly inhibited.
Ideally, a more speciﬁc inhibitor would need to be developed that
could completely inhibit PknB in vivo without its effects being
diluted by off-target binding.
Our work appears to have highlighted one of the difﬁculties
associated with target-based drug discovery: namely, that scre-
ening a relatively small library of inhibitors in vitro regularly fails to
yield compounds with potent in vivo activity. However, the suit-
ability of PknB as a drug target cannot yet be refuted. Our discovery
of inhibitors with good in vitro activity and modest in vivo activity
suggests that further screening on a larger scale may yet yield
potent inhibitors able to completely inhibit the activity of PknB in
vivo. To take into account the possibility of redundancy among the
kinases, we believe further attempts to develop M. tuberculosis
kinase inhibitors might usefully target a broad speciﬁcity inhibitor
targeting multiple kinases as suggested by Hegymegi-Barakonyi
et al.13Funding: This workwas supported byMRC Technology through
a grant from the MRCT Development Gap Fund (A853-0058) and by
the Medical Research Council (U117585867 and U117584228).
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